Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AZ's Gout Drug Gets FDA Go-Ahead With Safety Caveats

This article was originally published in Scrip

Executive Summary

The US FDA has approved AstraZeneca's Zurampic (lesinurad) to treat treat high levels of uric acid in the blood associated with gout. The approval, for its use in combination with a xanthine oxidase inhibitor (or XOI, such as allopurinol or febuxostat, which reduce uric acid production), is conditional upon AstraZeneca completing a postmarketing study to further evaluate the drug's renal and cardiovascular safety. Zurampic has a boxed warning about the raised risk of acute kidney failure when Zurampic is used without an XOI and with higher than approved doses.


Related Content

Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement